Kiromic BioPharma (FRA:5JU0) Debt-to-EBITDA : -0.75 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Kiromic BioPharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kiromic BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €11.81 Mil. Kiromic BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.69 Mil. Kiromic BioPharma's annualized EBITDA for the quarter that ended in Mar. 2024 was €-16.63 Mil. Kiromic BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.75.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kiromic BioPharma's Debt-to-EBITDA or its related term are showing as below:

FRA:5JU0' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.92 Med: -0.16 Max: -0.02
Current: -0.79

During the past 6 years, the highest Debt-to-EBITDA Ratio of Kiromic BioPharma was -0.02. The lowest was -0.92. And the median was -0.16.

FRA:5JU0's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs FRA:5JU0: -0.79

Kiromic BioPharma Debt-to-EBITDA Historical Data

The historical data trend for Kiromic BioPharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Debt-to-EBITDA Chart

Kiromic BioPharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.03

-0.02

-0.29

-0.92

Kiromic BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.70	-0.43	-0.89	-1.11	-0.75

Competitive Comparison of Kiromic BioPharma's Debt-to-EBITDA

For the Biotechnology subindustry, Kiromic BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiromic BioPharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Debt-to-EBITDA falls into.

Kiromic BioPharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kiromic BioPharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.417	+	0.836)	/	-15.475
	=	-0.92

Kiromic BioPharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(11.807	+	0.687)	/	-16.632
	=	-0.75

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Kiromic BioPharma (FRA:5JU0) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Kiromic BioPharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiromic BioPharma (FRA:5JU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (FRA:5JU0) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

KRBP:USA

Address

7707 Fannin Street, Suite 140, Houston, TX, USA, 77054

Website

https://www.kiromic.com

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Kiromic BioPharma (FRA:5JU0) Headlines

No Headlines